Merck has Requested Re-examination of the CHMP Opinion for Erbitux in Non-Small Cell Lung Cancer
03-Aug-2009
- Germany
The decision to request re-examination follows consultation with key stakeholders in the NSCLC treatment community, coupled with Merck’s confidence in the clinical data supporting Erbitux in this potential indication.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.